Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) at the end of treatment (EOT) and 24 weeks af...

Descripción completa

Detalles Bibliográficos
Autores principales: Akbar, Sheikh Mohammad Fazle, Al Mahtab, Mamun, Aguilar, Julio Cesar, Yoshida, Osamu, Penton, Eduardo, Gerardo, Guillen Nieto, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619282/
https://www.ncbi.nlm.nih.gov/pubmed/34832596
http://dx.doi.org/10.3390/pathogens10111440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619282/
https://www.ncbi.nlm.nih.gov/pubmed/34832596
http://dx.doi.org/10.3390/pathogens10111440

Ejemplares similares